Compare iShares Gold Trust (IAU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Medpace Holdings Inc — how do they compare? iShares Gold Trust trades at $78.86 (market cap $61.51B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: iShares Gold Trust is far larger — about 3.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Medpace Holdings Inc for 14 Days on average.
| IAU | MEDP | |
|---|---|---|
Market Cap | $61.51B | $16.82B |
Volume | 3,206,729 | 223,093 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $630.19 |
52-Week Low | $74.21 | $393.42 |
Typical Hold Time | 49 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.88, up 2.36% with a $1.82 daily gain, though technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, with support levels at $76-$77 and resistance at $78-$79. Recent news highlights gold's sensitivity to inflation data and interest rate expectations.
The outlook remains cautious due to macroeconomic headwinds and technical weakness. Investment opportunities exist if gold prices stabilize amid inflation concerns, but risks include persistent rate hikes and dollar strength. Monitor Fed policy and economic data for directional cues.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
